Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A rare inherited leukodystrophy characterized by progressive presenile dementia associated with recurrent bone fractures due to polycystic osseous lesions of the lower and upper extremities.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 16 | Hydrocephalus, Atypical behavior, Frontal lobe dementia |
Bones and joints | 6 | Limitation of joint mobility, Skeletal dysplasia, Bone pain |
Muscles | 2 | Limitation of joint mobility, Cerebral cortical atrophy |
Eyes | 1 | Oculomotor apraxia |
Digestive system | 1 | Functional abnormality of the gastrointestinal tract |
Age of onset: adulthood.
The clinical course of polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy (PLOSL) can be divided into four stages: latent, osseous, early neurologic, and late neurologic . Latent stage. Early development is normal. Osseous stage (3rd decade of life). The first symptoms of PLOSL appear in early adulthood as pain and tenderness, mostly in the ankles and feet, usually following strain or a minor accident. Fractures are typically diagnosed several years later, most commonly in the bones of the extremities . The first fractures usually occur shortly before age 30 years; however, affected individuals may have had pain and swelling of the ankles and wrists after strain for years. The fractures heal well.
Source: GeneReviews — "Polycystic Lipomembranous Osteodysplasia with Sclerosing Leukoencephalopathy"
No consensus clinical diagnostic criteria for polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy (PLOSL) have been published.
PLOSL should be suspected in individuals with the following features:
Source: GeneReviews — "Polycystic Lipomembranous Osteodysplasia with Sclerosing Leukoencephalopathy"
The combination of frontal-type dementia beginning in the fourth decade and radiologically demonstrable polycystic osseous lesions makes it easy to clinically distinguish polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy (PLOSL) from the established forms of familial and nonfamilial frontotemporal dementia (e.g., Pick disease, nonspecific frontal lobe degeneration, CSF1R adult-onset leukoencephalopathy with axonal spheroids and pigmented glia, and the various entities of frontotemporal dementia and parkinsonism linked to pathogenic variants in MAPT).
Source: GeneReviews — "Polycystic Lipomembranous Osteodysplasia with Sclerosing Leukoencephalopathy"
No approved treatments are currently available for polycystic lipomembranous osteodysplasia with sclerosing leukoencephaly. The disease remains an area of unmet medical need.
No clinical practice guidelines for polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy (PLOSL) have been published. Evaluations Following Initial Diagnosis To establish the extent of disease and needs in an individual diagnosed with PLOSL, the evaluations summarized (if not performed as part of the evaluation that led to the diagnosis) are recommended. Table 3. Recommended Evaluations Following Initial Diagnosis in Individuals with Polycystic Lipomembranous Osteodysplasia with Sclerosing Leukoencephalopathy
System/Concern | Evaluation | Comment |
|---|---|---|
osseous lesions | Radiographs of bones of wrists, hands, ankles, feet | To determine extent of osseous manifestations; A plain radiograph must be taken if skeletal pain due to risk of pathologic fracture. Neurologic |
manifestations | Brain CT /or MRI | To determine extent of CNS manifestations Neurologic neuropsychological exam |
counseling | By genetics professionals1 | To inform affected persons their families re nature, MOI, implications of PLOSL to facilitate medical personal decision making CNS = central nervous system; MOI = mode of inheritance 1. |
Manifestation/Concern | Treatment | Considerations/Other Polycystic osseous |
lesions | Standard orthopedic management of fractures |
Source: GeneReviews — "Polycystic Lipomembranous Osteodysplasia with Sclerosing Leukoencephalopathy"
Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.
Source: GeneReviews — "Polycystic Lipomembranous Osteodysplasia with Sclerosing Leukoencephalopathy"
View trials for polycystic lipomembranous osteodysplasia with sclerosing leukoencephaly
The interval of surveillance for bone lesions, neurologic, and psychiatric manifestations must be determined individually.
Table 5.
Recommended Surveillance for Individuals with Polycystic Lipomembranous Osteodysplasia with Sclerosing Leukoencephalopathy
System/Concern | Evaluation | Frequency
| Clinical eval for evidence of fractures | Must be determined on an individual basis
| Neurologic exam
| Neuropsychological exam
Source: GeneReviews — "Polycystic Lipomembranous Osteodysplasia with Sclerosing Leukoencephalopathy"
Phenotype severity distribution: 17 very common features, 8 common features.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for polycystic lipomembranous osteodysplasia with sclerosing leukoencephaly.
18 publications have been identified in PubMed for polycystic lipomembranous osteodysplasia with sclerosing leukoencephaly. Research spans Review / Meta-Analysis (33%), Basic Science / Preclinical (33%), and Case Report / Case Series (17%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 6 | 33% |
Laboratory research | 6 | 33% |
Patient case studies | 3 | 17% |
New treatment approaches | 2 | 11% |
Other research | 1 | 6% |
Mallika AP (2026). [PMID: 41817071](https://pubmed.ncbi.nlm.nih.gov/41817071/). *Neurol India*. [Case Report / Case Series]
Bokhari BT (2026). [PMID: 41719345](https://pubmed.ncbi.nlm.nih.gov/41719345/). *PLoS One*. [Gene Therapy / Novel Therapeutics]
Hol EM (2025). [PMID: 40148043](https://pubmed.ncbi.nlm.nih.gov/40148043/). *Handb Clin Neurol*. [Review / Meta-Analysis]
Göttert R (2025). [PMID: 39879812](https://pubmed.ncbi.nlm.nih.gov/39879812/). *Stem Cell Res*. [Basic Science / Preclinical]
Diniz JRG (2025). [PMID: 40822322](https://pubmed.ncbi.nlm.nih.gov/40822322/). *Dement Neuropsychol*. [Case Report / Case Series]
Yang H (2025). [PMID: 40806186](https://pubmed.ncbi.nlm.nih.gov/40806186/). *Int J Mol Sci*. [Review / Meta-Analysis]
Verkhratsky A (2025). [PMID: 40500501](https://pubmed.ncbi.nlm.nih.gov/40500501/). *Adv Neurobiol*. [Review / Meta-Analysis]
Qi X (2025). [PMID: 41168805](https://pubmed.ncbi.nlm.nih.gov/41168805/). *Transl Neurodegener*. [Review / Meta-Analysis]
Sarkar Z (2025). [PMID: 41510405](https://pubmed.ncbi.nlm.nih.gov/41510405/). *Cureus*. [Case Report / Case Series]
Pillai J (2025). [PMID: 40687989](https://pubmed.ncbi.nlm.nih.gov/40687989/). *Comput Struct Biotechnol J*. [Gene Therapy / Novel Therapeutics]
Data assembled from 5 of 12 sources · Last updated Sep 20, 2026, 10:23 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Pain mgmt following treatment of osseous lesions |
manifestations | Psychotropic drugs | Insufficient data available Psychological support early education of family members re nature of disorder |
Epileptic seizures | Anti-seizure medication | The interval of surveillance for bone lesions, neurologic, and psychiatric manifestations must be determined individually. Recommended Surveillance for Individuals with Polycystic Lipomembranous Osteodysplasia with Sclerosing Leukoencephalopathy |
System/Concern | Evaluation | Frequency |
Polycystic osseous lesions | Clinical eval for evidence of fractures | Must be determined on an individual basis Neurologic manifestations |